Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.76 |
| ▸ | CDK4 | P11802 | 11/20 | 0.76 |
| ▸ | EIF2AK2 | P19525 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600525 | 0.88 | CDK2 (0.74) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4615351 | 0.87 | CDK4 (1.00) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4616002 | 0.85 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL4613384 | 0.84 | CDK2 (1.00) | CDK2CDK4EIF2AK2SYK | |
| SCHEMBL6600207 | 0.83 | CDK4 (0.87) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4613825 | 0.80 | CDK2 (0.85) | CDK2CDK4EIF2AK2GSK3B | |
| SCHEMBL4613710 | 0.76 | CDK4 (1.00) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4613588 | 0.76 | CDK4 (0.78) | CDK2CDK4EIF2AK2 | |
| SCHEMBL6599785 | 0.76 | CDK2 (0.52) | CDK2CDK4EIF2AK2KCNH2GSK3B | |
| SCHEMBL4615069 | 0.76 | CDK4 (0.80) | CDK2CDK4EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373253-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | Cyclacel Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079193-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AS ANTI-CANCER AGENT | CYCLACEL LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |